Article Abstract

Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option

Authors: Antonio Passaro, Filippo de Marinis


The identification of EGFR mutations in non-small cell lung cancer (NSCLC) changed deeply the treatment of this disease harbouring these kind of DNA alterations, that occur respectively in about 10–15% and 45–50% of Caucasian and Asian patients (1,2).